{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:26:44Z","timestamp":1792614404498,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jtha.2024.07.006","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T20:03:31Z","timestamp":1721073811000},"page":"2864-2872","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Tinzaparin, an alternative to subcutaneous unfractionated heparin, in patients with severe and end-stage renal impairment: a retrospective observational single-center study"],"prefix":"10.1016","volume":"22","author":[{"given":"Isabelle","family":"Gouin-Thibault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charl\u00e8ne","family":"Caribotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Pierre-Jean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Bouzille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Ballerie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Maucorps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Gueret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"N\u00e9delec-Gac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Pontis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Vannier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Behar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Cardiet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Mismetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Frouget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Delavenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.07.006_bib1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/jth.12141","article-title":"Risk of venous thrombosis in patients with chronic kidney disease: identification of high-risk groups","volume":"11","author":"Ocak","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.006_bib2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.amjmed.2012.09.021","article-title":"Low-molecular-weight or unfractionated heparin in venous thromboembolism: the influence of renal function","volume":"126","author":"Trujillo-Santos","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.jtha.2024.07.006_bib3","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2024.07.006_bib4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2024.07.006_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/1076029620979592","article-title":"Tinzaparin safety in patients with cancer and renal impairment: a systematic review","volume":"27","author":"Vathiotis","year":"2021","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jtha.2024.07.006_bib6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.7326\/0003-4819-144-9-200605020-00011","article-title":"Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency","volume":"144","author":"Lim","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2024.07.006_bib7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00228-011-1149-6","article-title":"Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: a meta-analysis","volume":"68","author":"Hoffmann","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2024.07.006_bib8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s40256-019-00382-0","article-title":"Tinzaparin sodium pharmacokinetics in patients with chronic kidney disease: practical implications","volume":"20","author":"Helfer","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jtha.2024.07.006_bib9","unstructured":"European Medicines Agency. Enoxaparin sodium. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/lovenox-article-30-referral-annex-iii_en.pdf. [accessed August 2, 2024]."},{"key":"10.1016\/j.jtha.2024.07.006_bib10","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2165\/00002018-200225100-00005","article-title":"Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients","volume":"25","author":"Pautas","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.jtha.2024.07.006_bib11","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1055\/s-0037-1614119","article-title":"Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU\/kg): anti-Xa and anti-IIa activities over 10 days","volume":"84","author":"Siguret","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.006_bib12","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1111\/j.1538-7836.2011.04458.x","article-title":"No accumulation of the peak anti-factor Xa activity of tinzaparin in elderly patients with moderate-to-severe renal impairment: the IRIS substudy","volume":"9","author":"Siguret","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.006_bib13","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1053\/ajkd.2002.34911","article-title":"Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis","volume":"40","author":"Hainer","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jtha.2024.07.006_bib14","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1160\/TH06-09-0513","article-title":"Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study","volume":"97","author":"Mah\u00e9","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.006_bib15","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1055\/s-0038-1641150","article-title":"Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism\u2014analysis of the CATCH study","volume":"118","author":"Bauersachs","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.006_bib16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000477474","article-title":"Empirically reduced dosages of tinzaparin in patients with moderate-to-severe renal insufficiency lead to inadequate anti-Xa levels","volume":"137","author":"Olie","year":"2017","journal-title":"Nephron"},{"key":"10.1016\/j.jtha.2024.07.006_bib18","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJM198610303151801","article-title":"Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis","volume":"315","author":"Hull","year":"1986","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.07.006_bib19","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1001\/archinte.1988.00380060085018","article-title":"Physician practices in the treatment of pulmonary embolism and deep venous thrombosis","volume":"148","author":"Wheeler","year":"1988","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jtha.2024.07.006_bib20","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.006_bib21","first-page":"1536","article-title":"eHOP clinical data warehouse: from a prototype to the creation of an inter-regional clinical data centers network","volume":"264","author":"Madec","year":"2019","journal-title":"Stud Health Technol Inform"},{"key":"10.1016\/j.jtha.2024.07.006_bib22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1051\/ps:2004007","article-title":"Coupling a stochastic approximation version of EM with an MCMC procedure","volume":"8","author":"Kuhn","year":"2004","journal-title":"ESAIM Prob Stat"},{"key":"10.1016\/j.jtha.2024.07.006_bib23","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.csda.2006.05.007","article-title":"Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: application to HIV dynamics model","volume":"51","author":"Samson","year":"2006","journal-title":"Comput Stat Data Anal"},{"key":"10.1016\/j.jtha.2024.07.006_bib24","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1093\/ajhp\/58.17.1614","article-title":"Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers","volume":"58","author":"Fossler","year":"2001","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jtha.2024.07.006_bib25","unstructured":"FDA. Innohep (tinzaparin sodium injection)."},{"key":"10.1016\/j.jtha.2024.07.006_bib26","first-page":"431","article-title":"Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis","volume":"39","author":"Barrett","year":"2001","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.jtha.2024.07.006_bib27","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1046\/j.0007-1048.2001.03306.x","article-title":"The pharmacodynamics of tinzaparin in healthy volunteers: short report","volume":"116","author":"Cambus","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.07.006_bib28","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1055\/s-2001-17961","article-title":"How and when to monitor a patient treated with low molecular weight heparin","volume":"27","author":"Boneu","year":"2001","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2024.07.006_bib29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.thromres.2018.11.031","article-title":"Study of the bioaccumulation of tinzaparin in renally impaired patients when given at prophylactic doses - the STRIP study","volume":"174","author":"Projean","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.07.006_bib30","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00228-015-1880-5","article-title":"A\u00a0systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency","volume":"71","author":"Atiq","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2024.07.006_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.thromres.2011.03.002","article-title":"Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep\u00ae in Renal Insufficiency Study (IRIS)","volume":"128","author":"Leizorovicz","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.07.006_bib32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00002512-200724010-00005","article-title":"Elderly medical patients treated with prophylactic dosages of enoxaparin: influence of renal function on anti-Xa activity level","volume":"24","author":"Mahe","year":"2007","journal-title":"Drugs Aging"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624004239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624004239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T20:45:55Z","timestamp":1759351555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624004239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1538783624004239"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.07.006","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tinzaparin, an alternative to subcutaneous unfractionated heparin, in patients with severe and end-stage renal impairment: a retrospective observational single-center study","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}